The UAB Institutional Biosafety Committee Meeting Minutes
Research Involving Recombinant and Synthetic Nucleic Acid Molecules
October 13, 2025 12:30 pm

Members	Present (Y/N)	Vote (Y/N)
1. Joel N. Glasgow, PhD, Chair [JNG]	Y	Y
2. Megan Kiedrowski, PhD, Vice-Chair [MRK]	Y	Y
3. Donna Williamson, MS, RSS [DSW]	Y	Y
4. Amanda F. Smith, BS, RSS, Voting Contact [AFS]	Y	N
5. Cameron Crosby, MD, OM [JCC]	Y	Y
6. Julie Allen, DNP, OM [JSA]	Y	N
7. Lillie Flood, RN-BSN, JCDH [LF]	Y	Y
8. Qiang (John) Ding, PhD, VA [QJD]	Y	Y
9. Andrea Osborne, DVM, ARP [AJO]	Y	Y
10. Justin Roth, PhD, BSO-EHS [JCR]	N	N
11. Brian Lagory, BS, BSO-EHS [BEL]	Y	Y
12. Vineel Reddy, PhD, EHS [VPR]	Y	Y
13. Julie Gray, BS, EHS [JDG]	Y	N
14. Tyler Uzzell, MA, IRB [TWU]	N	N
15. Amanda J. Watts, MS, IACUC [AJW]	Y	Y
16. Chad Dunaway, IACUC [CD]	N	N
17. Tyler T. Wright, PhD, Lab Rep [TTW]	Y	Y
18. Masakazu Kamata, PhD, Lab Rep [MK]	Y	Y
19. Kevin Harrod, PhD, Lab Rep [KH]	N	N
20. Christine M. Wright, PhD, Lab Rep [CMW]	N	N
21. Larisa Pereboeva, PhD, Lab Rep [LP]	N	N
22. Theresa Strong, PhD, Lab Rep [TVS]	Y	Y
23. Aftab Ahmad, PhD, Lab Rep [AA]	Y	Y
24. Adam McClintock, MBA, HSR [AM]	N	N
25. Wesley Willeford, MD, JCDH [WW]	Y	Y
26. Rebecca Johnstone, RSS, Recording Secretary [RMJ]	Y	N
Total	**19**	**15**

Guests Present

Laura Caltrider, EHS [LPC]	Stephen Geisler, JD [SG]
Earle Durboraw, ARP [EBD]	Caitlyn Sebastian, Biomed Sciences [CS]
Joseph Palmer, SEBLAB [JP]	K. Lee Stone, MS, MT EHS [KLS]
Douglas Fox, SEBLAB [DMF]	Laura Cornett, ARP [LC]
Luselyz Ortiz Torres, EHS [LOT]	Dale Payton, ARP [DP]

The October 13, 2025, Institutional Biosafety Committee (IBC) meeting for Research Involving Recombinant of Synthetic Nucleic Acid Molecules was called to order at 12:33 pm via web-based video conferencing tool by JNG. A quorum was present.

Welcome and Introduction of Guests
JNG welcomed all in attendance.

Approval of the September 08, 2025, Minutes
The September 08, 2025, meeting minutes were distributed in the Committee member packet via email and/or secure cloud storage prior to the meeting. A motion was made to approve the minutes. The motion was seconded. There were two abstentions. The minutes were approved.

Standing Reports
- In the News/Regulatory Visits – Government Shutdown has impacted some of the grants and SEBLAB functionality as far as communication.
- Faculty Senate – There were no updates.
- Veterans Administration – There were no updates.
- Employee Health – There were no updates.
- JCDH – Covid season is winding down.
- IRAP and EHSA – The bioform in EHSA is still being updated.
- Research Safety Updates:
  - PI Arrivals/Departures/UAB Lab Relocations – Arrivals: Departures: Hope Am
  - Safety Visits – Top 5: Chemical inventory, Ethanol usage log, Peroxide formers labels, chemical storage, and secondary containment

New/Old Business
The Viral Vectors SOP was updated to include modification for autoclave usage and cage change frequency. It was noted that the policy verbiage needs to be updated to an SOP. ARP discussed timelines and training methods to implement the updates.

Project Review
The review and discussion of the projects provided on the attached table included: agent characteristics; types of manipulations planned; verification that the PI and laboratory staff performing the research have been appropriately trained in the safe conduct of the research; and containment control measures to be implemented (biosafety level and any special provisions). Please refer to the attached summary of the Committee review outcome for each project.

Transgenic Projects
No transgenic projects were discussed at this meeting.

Adjournment
The Chair asked if there were any further questions or comments. Being none, the meeting was adjourned at 1:48 pm. The next meeting date is November 10, 2025.

Respectfully submitted by:



Rebecca Johnstone, Recording Secretary
Research Safety Committees

Project registration documents submitted by the PI indicate UAB Institutional Biosafety Committee (IBC) review and approval is required for the following research activities involving recombinant or synthetic nucleic acid (r/sNA) molecules and/or biohazardous agents. If the nature of the work changes or the listed conditions cannot be met, it is the PI's responsibility to consult with the IBC for additional guidance. It is the PI's responsibility to ensure all individuals listed on the project are enrolled in and compliant with the requirements of UAB Employee Health prior to and for the duration of the work:

Approve	Disapprove	Abstain or Recuse	RSC #	Evaluation
15	--	--	25-175	(III.C.1) **WCG IRB: A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel cersus Standard of Care in patients suffereing from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)** For: • Administration of patient-derived genetically engineered CAR T cells expressing an anti-CD19 antibody-based synthetic receptor to one or more human subjects Containment: • Universal Precautions should be used for handling and administration of the IP. • Dispose of excess IP and ancillary contaminated materials per Sponsor Instructions or per institutional guidelines.
15	--	--	19-178	(III.D.1.a) **Engineered Herpes Simplex Viruses for Treatment of Intraparenchymal Brain Tumors and Leptomeningeal Metastases** For: • Administration of recombinant RG-2 viruses to animals Containment: • BSL-2 • ABSL-2 • Annually certified BSC for all work with oHSV, with the exception of stereotactic injections and all animal handling and cage changes 14-day post-administration • Proper cages and cage racks needed for ABSL-2 housing, in non-static caging is in use. • Expected decontamination procedures prior to removal of the AUSI • AUSI for oHSV • Autoclave cages and bedding for 14-days post administration

15	--	--	25-116	(III.D.1; III.D.4.b) **Non-tuberculous mycobacterium and B cells in the stimulation of ectopic germinal centers and immunological control of pulmonary tuberculosis** For: • 2 strains of attenuated auxotrophic mycobacterium tuberculosis (M.tb) strains Containment: • BSL-2 • ABSL-2 • BSC for all the in vitro and in vivo work related to these attenuated strains • AUSI for animals treated with auxotroph strains for the duration of the experiment at ABSL-2/ARP facility • Autoclave dirty cages with bedding prior to cleaning and disposal at ABSL-2.
15	--	--	25-125	(III.D.1.a; III.D.4.b) **Gene Therapy Studies in Transgenic Ferret Models** For: • Administration of recombinant Influenza A Virus (IAV), a Risk Group 2 organism, to ferrets, including transgenic animals Containment: • A/BSL2 practices and procedures, including the use of a BSC, is required for work with influenza viruses and influenza infected ferrets. • Working with two different influenza strains concurrently is not allowed; however, working with a recombinant and wild type of the same strain may be done concurrently. • AUSI required for IAV, the previous AUSI for AAV/viral vectors remains in effect, and N95 along with disposable gown and gloves will be worn when in rooms with AUSI posted (influenza or AAV). • Cages/bedding from influenza infected ferrets must be autoclaved. If an autoclave is not available where the ferrets are housed, an EHS approved plan/SOP must be in place for proper disinfection and/or transportation of caging to an autoclave in another facility prior to transfer of caging/bedding. • Infected animals must be transported to the imaging facility in their isolation cages inside a secondary sealed container by ARP, and a copy of the AUSI must accompany the animals. • During imaging, the room must be locked, the AUSI posted, and all individuals working with animals must wear fitted N-95s, gloves, and disposable gowns. • For the imaging location, the PI must have an approved disinfection SOP on file that includes appropriate disinfectant, contact time, disposal of contaminated and/or cleaning materials, and holding time prior to the room being released after removal of ferrets.

15	--	--	25-178	III.D.1; III.E **Development of cancer treatments** **For:** • Direct administration of recombinant Adenoviral vectors to animals • Use of non-K12 derived r/sNA E. coli (BL21) Containment: • BSL2 practice and procedures, including the use of an annually certified BSC, must be used for in vitro manipulations of Ad5. • ABSL2 practices and procedures, including the use of an annually certified BSC and an AUSI, must be used for administration and for 14 days after administration of Ad5. • Biohazard waste disposal must be used for all BL21 waste.
15	--	--	23-147	(III.D.4.b) **Gene Therapy Studies in Transgenic Ferret Models** For: • Administration of BCG vaccine to animals Containment: • ABSL-2 practices and procedures, including an annually certified BSC, must be used for all work with BCG. • An AUSI must be posted for mice treated with BCG strain for the duration of experiment.
15	--	--	25-149	(III.D.3) **Neural circuit mechanisms underlying postpartum social cognitive impairment induced by adolescent stress** For: • Administration of Adeno-associated viral (AAV) vectors to animals Containment: • ABSL2 practices and procedures, including the posting of an AUSI, must be used for 14 days after administration of AAV to animals
16	--	--	25-181	(III.D.4.a) **Non-viral vector based follistatin gene therapy for the treatment of ischemic heart and limb diseases** For: • Administration of rsNA plasmids to animals Containment: • ABSL1 for administration of plasmids